ABSTRACT
Lipid-coated poly(lactide-co-glycolide) microparticles (LCMPs) consist of a solid polymer core wrapped by a surface lipid bilayer. Previous studies demonstrated that immunization with LCMPs surface-decorated with nanograms of antigen elicit potent humoral immune responses in mice. However, the mechanism of action for these vaccines remained unclear, as LCMPs are too large to drain efficiently to lymph nodes from the vaccination site. Here, we characterized the stability of the lipid envelope of LCMPs and discovered that in the presence of serum the lipid coating of the particles spontaneously delaminates, shedding antigen-displaying vesicles. Lipid delamination generated 180 nm liposomes in a temperature- and lipid/serum-dependent manner. Vesicle shedding was restricted by inclusion of high-TM lipids or cholesterol in the LCMP coating. Administration of LCMPs bearing stabilized lipid envelopes generated weaker antibody responses than those of shedding-competent LCMPs, suggesting that in situ release of antigen-loaded vesicles plays a key role in the remarkable potency of LCMPs as vaccine adjuvants.
Subject(s)
Adjuvants, Immunologic/chemistry , Lactic Acid/chemistry , Polyglycolic Acid/chemistry , Vaccines/chemistry , Adjuvants, Immunologic/pharmacology , Animals , Coated Materials, Biocompatible/chemistry , Coated Materials, Biocompatible/pharmacology , Female , Lactic Acid/pharmacology , Liposomes , Mice , Mice, Inbred BALB C , Nanoparticles/chemistry , Polyglycolic Acid/pharmacology , Polylactic Acid-Polyglycolic Acid Copolymer , Polymers/chemistryABSTRACT
Molecular adjuvants based off of pattern recognition receptor agonists are capable of potently stimulating innate immunity and inducing protective immune responses to subunit antigens. One significant disadvantage to these small molecule adjuvants is their pharmacokinetic profile of entering the blood stream rather than the lymphatics after parental injection. In order to target molecular adjuvants to lymph nodes, we have developed nanoparticle carriers whose size has been optimized to avoid the blood and efficiently drain to lymph nodes (Hanson et al. Vaccine 33:861-8,2015; Hanson et al. J Clin Invest 125:2532-2546, 2015). This chapter describes in detail the materials and procedures necessary to synthesize liposome nanoparticle carriers of either hydrophobic or hydrophilic adjuvants, including synthesis tips, alternative equipment options, and pitfalls to avoid.
Subject(s)
Adjuvants, Immunologic/chemistry , Adjuvants, Immunologic/chemical synthesis , Lymph Nodes , Nanoparticles/chemistry , Adjuvants, Immunologic/pharmacokinetics , Adjuvants, Immunologic/pharmacology , Animals , Humans , LiposomesABSTRACT
Cyclic dinucleotides (CDNs) are agonists of stimulator of IFN genes (STING) and have potential as vaccine adjuvants. However, cyclic di-GMP (cdGMP) injected s.c. shows minimal uptake into lymphatics/draining lymph nodes (dLNs) and instead is rapidly distributed to the bloodstream, leading to systemic inflammation. Here, we encapsulated cdGMP within PEGylated lipid nanoparticles (NP-cdGMP) to redirect this adjuvant to dLNs. Compared with unformulated CDNs, encapsulation blocked systemic dissemination and markedly enhanced dLN accumulation in murine models. Delivery of NP-cdGMP increased CD8+ T cell responses primed by peptide vaccines and enhanced therapeutic antitumor immunity. A combination of a poorly immunogenic liposomal HIV gp41 peptide antigen and NP-cdGMP robustly induced type I IFN in dLNs, induced a greater expansion of vaccine-specific CD4+ T cells, and greatly increased germinal center B cell differentiation in dLNs compared with a combination of liposomal HIV gp41 and soluble CDN. Further, NP-cdGMP promoted durable antibody titers that were substantially higher than those promoted by the well-studied TLR agonist monophosphoryl lipid A and comparable to a much larger dose of unformulated cdGMP, without the systemic toxicity of the latter. These results demonstrate that nanoparticulate delivery safely targets CDNs to the dLNs and enhances the efficacy of this adjuvant. Moreover, this approach can be broadly applied to other small-molecule immunomodulators of interest for vaccines and immunotherapy.
Subject(s)
Adjuvants, Immunologic , Cyclic GMP/analogs & derivatives , Drug Delivery Systems , Lipid A/analogs & derivatives , Lymph Nodes/immunology , Membrane Proteins/agonists , Nanoparticles/chemistry , AIDS Vaccines/immunology , AIDS Vaccines/pharmacology , Adjuvants, Immunologic/chemistry , Adjuvants, Immunologic/pharmacology , Animals , Cyclic GMP/chemistry , Cyclic GMP/pharmacology , HIV Envelope Protein gp41/immunology , HIV Envelope Protein gp41/pharmacology , HIV-1/immunology , Lipid A/chemistry , Lipid A/pharmacology , Membrane Proteins/immunology , Mice , Mice, Inbred BALB C , Polyethylene Glycols/chemistry , Polyethylene Glycols/pharmacologyABSTRACT
An HIV vaccine capable of inducing high and durable levels of broadly neutralizing antibodies has thus far proven elusive. A promising antigen is the membrane-proximal external region (MPER) from gp41, a segment of the viral envelope recognized by a number of broadly neutralizing antibodies. Though an attractive vaccine target due to the linear nature of the epitope and its highly conserved sequence, MPER peptides are poorly immunogenic and may require display on membranes to achieve a physiological conformation matching the native virus. Here we systematically explored how the structure and composition of liposomes displaying MPER peptides impacts the strength and durability of humoral responses to this antigen as well as helper T-cell responses in mice. Administration of MPER peptides anchored to the surface of liposomes induced MPER-specific antibodies whereas MPER administered in oil-based emulsion adjuvants or alum did not, even when combined with Toll-like receptor agonists. High-titer IgG responses to liposomal MPER required the inclusion of molecular adjuvants such as monophosphoryl lipid A. Anti-MPER humoral responses were further enhanced by incorporating high-Tm lipids in the vesicle bilayer and optimizing the MPER density to a mean distance of â¼10-15 nm between peptides on the liposomes' surfaces. Encapsulation of helper epitopes within the vesicles allowed efficient "intrastructural" T-cell help, which promoted IgG responses to MPER while minimizing competing B-cell responses against the helper sequence. These results define several key properties of liposome formulations that promote durable, high-titer antibody responses against MPER peptides, which will be a prerequisite for a successful MPER-targeting vaccine.
Subject(s)
AIDS Vaccines/immunology , AIDS Vaccines/therapeutic use , Liposomes/chemistry , T-Lymphocytes/immunology , AIDS Vaccines/chemistry , Animals , Antibody Formation/immunology , Female , HIV Envelope Protein gp41/immunology , Mice , Mice, Inbred BALB C , Nanoparticles/chemistryABSTRACT
gp120 is a substrate for protein engineering both for human immunodeficiency virus (HIV) immunogen design and as a bait for isolating anti-HIV antibodies from patient samples. In this work, we describe the display of a stripped core gp120 on the yeast cell surface. Validation against a panel of neutralizing antibodies confirms that yeast-displayed gp120 presents the CD4 binding site in the correct conformation. We map the epitope of the broadly neutralizing anti-gp120 antibody VRC01 using both a random mutagenesis library and a defined mutant panel and find that the resultant epitope maps are consistent with one another and with the crystallographically identified contact residues. Mapping the VRC01-competitive antibodies b12 and b13 reveals energetic differences in their epitopes that are not obvious from existing crystal structures. These data suggest mutation sets that abrogate binding to broadly neutralizing antibodies with greater specificity than the canonical mutation D368R, useful in rapidly assessing the nature of a vaccine response.
Subject(s)
Antibodies, Anti-Idiotypic/immunology , Antibodies, Neutralizing/immunology , Drug Design , Epitope Mapping , Epitopes/immunology , HIV Antibodies/immunology , HIV Envelope Protein gp120/immunology , Saccharomyces cerevisiae/immunology , Antibodies, Anti-Idiotypic/chemistry , Antibodies, Anti-Idiotypic/metabolism , Antibodies, Neutralizing/genetics , Antibodies, Neutralizing/isolation & purification , CD4 Antigens/genetics , CD4 Antigens/immunology , CD4 Antigens/metabolism , Cells, Cultured , Epitopes/genetics , Epitopes/metabolism , Flow Cytometry , HIV Antibodies/genetics , HIV Antibodies/metabolism , HIV Envelope Protein gp120/genetics , HIV Envelope Protein gp120/metabolism , Humans , Kidney/cytology , Kidney/metabolism , Mutagenesis , Mutant Proteins/genetics , Mutant Proteins/immunology , Mutant Proteins/metabolism , Peptide Library , Protein Conformation , Protein Engineering , Saccharomyces cerevisiae/metabolismABSTRACT
New subunit vaccine formulations with increased potency are of interest to improve immune responses against poorly immunogenic antigens, to avoid vaccine shortages in pandemic situations, and to promote dose-sparing of potent adjuvant molecules that can cause unacceptable side effects in prophylactic vaccination. Here we report strong class-switched, high avidity humoral immune responses elicited by a vaccine system based on poly(lactide-co-glycolide) micro- or nano-particles enveloped by PEGylated phospholipid bilayers, with protein antigens covalently anchored to the lipid surface and lipophilic adjuvants inserted in the bilayer coating. Strikingly, these particles elicited high endpoint antigen-specific IgG titers (>10(6)) sustained for over 100 days after two immunizations with as little as 2.5 ng of antigen. At such low doses, the conventional adjuvant alum or the molecular adjuvants monophosphoryl lipid A (MPLA) or α-galactosylceramide (αGC) failed to elicit responses. Co-delivery of antigen with MPLA or αGC incorporated into the particle bilayers in a pathogen-mimetic fashion further enhanced antibody titers by ~12-fold. MPLA provided the highest sustained IgG titers at these ultra-low antigen doses, while αGC promoted a rapid rise in serum IgG after one immunization, which may be valuable in emergencies such as disease pandemics. The dose of αGC required to boost the antibody response was also spared by particulate delivery. Lipid-enveloped biodegradable micro- and nano-particles thus provide a potent dose-sparing platform for vaccine delivery.
Subject(s)
Antigens/administration & dosage , Immunoglobulin G/blood , Lipids/administration & dosage , Nanoparticles/administration & dosage , Ovalbumin/administration & dosage , Vaccines, Subunit/administration & dosage , Adjuvants, Immunologic/administration & dosage , Animals , Biomimetics , Cells, Cultured , Dendritic Cells/drug effects , Dendritic Cells/immunology , Female , Galactosylceramides/administration & dosage , Lactic Acid/administration & dosage , Lipid A/administration & dosage , Lipid A/analogs & derivatives , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Transgenic , Polyglycolic Acid/administration & dosage , Polylactic Acid-Polyglycolic Acid Copolymer , T-Lymphocytes/drug effects , T-Lymphocytes/immunologyABSTRACT
Hydrogel networks crosslinked with polymer-bound phenylboronic acid (PBA) and salicylhydroxamic acid (SHA) demonstrate pH-reversible gel behavior due to the pH-dependent equilibrium of the crosslinking moieties that form the gel network. Furthermore, the pH at which gels behave dynamically can be controlled by use of a polyelectrolyte backbone. Here we report on the frequency-dependent chemorheological characterization of PBA-SHA crosslinked hydrogel networks with a sulfonated polymer backbone. Our results suggest that the anionic nature of the polymers allows reversible crosslinking at neutral pH that an otherwise neutral-backboned PBA-SHA crosslinked network cannot, and that these charge-induced dynamics can be effectively screened by ions in solution. Moreover, moduli-frequency data can effectively be reduced into a single master curve with a neutral-backboned PBA-SHA gel data set as the reference condition.